ginsenoside F1
Identification
| Name | ginsenoside F1 |
| CAS Number | 53963-43-2 |
| FDA UNII | Search |
| Molecular Formula | C36 H62 O9 |
| Molecular Weight | 638.88294000 |
| MDL Number | MFCD06410947 |
| Nikkaji Number | J38.859I |
Regulatory
Physical Properties
| Assay | 95.00 to 100.00 |
| Food Chemicals Codex Listed | No |
| Soluble in | water, 0.07331 mg/L @ 25 °C (est) |
No sensory data available
Safety Information
| Preferred SDS | View |
| Oral/Parenteral Toxicity | Not determined |
| Dermal Toxicity | Not determined |
| Inhalation Toxicity | Not determined |
GHS Classification
['GHS Classification in accordance with 29 CFR 1910 (OSHA HCS)', 'GHS Label elements, including precautionary statements']
Safety in Use
| Category | natural substances and extractives |
| Recommendation for ginsenoside F1 usage levels up to | not for fragrance use. |
| Recommendation for ginsenoside F1 flavor usage levels up to | not for flavor use. |
BOC Sciences
Best of Chemicals Supplier
Quality supplier of research chemicals and biochemicals including inhibitors, building blocks, GMP Products, impurities and metabolites, APIs for Veterinary, Natural Compounds, ADCs, Stem Cell Molecul...
Potential Uses
Natural Occurrence
Synonyms
beta-D-
glucopyranoside, (3beta,6aalpha,12beta)-3,6,12-trihydroxydammar-24-ene-20-yl
(2R,3S,4S,5R,6S)-2-(
hydroxymethyl)-6-[(2S)-6-methyl-2-[(3S,5R,6S,8R,9R,10R,12R,13R,14R,17S)-3,6,12-trihydroxy-4,4,8,10,14-pentamethyl-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]hept-5-en-2-yl]oxyoxane-3,4,5-triol
PubMed:
Ginsenoside F1 suppresses astrocytic senescence-associated secretory phenotype.
PubMed:
Rare ginsenoside Ia synthesized from F1 by cloning and overexpression of the UDP-glycosyltransferase gene from
Bacillus subtilis
: synthesis, characterization, and
in vitro
melanogenesis inhibition activity in BL6B16 cells.
PubMed:
Ginsenoside F1 Ameliorates Endothelial Cell Inflammatory Injury and Prevents Atherosclerosis in Mice through A20-Mediated Suppression of NF-kB Signaling.
PubMed:
Metabolic analysis of Panax notoginseng saponins with gut microbiota-mediated biotransformation by HPLC-DAD-Q-TOF-MS/MS.
PubMed:
Gram-Scale Production of Ginsenoside F1 Using a Recombinant Bacterial β-Glucosidase.
PubMed:
Production of ginsenoside F1 using commercial enzyme Cellulase KN.
PubMed:
Screening SIRT1 Activators from Medicinal Plants as Bioactive Compounds against Oxidative Damage in Mitochondrial Function.
PubMed:
Characterization of Panax ginseng UDP-Glycosyltransferases Catalyzing Protopanaxatriol and Biosyntheses of Bioactive Ginsenosides F1 and Rh1 in Metabolically Engineered Yeasts.
PubMed:
Ginsenoside F1 attenuates hyperpigmentation in B16F10 melanoma cells by inducing dendrite retraction and activating Rho signalling.
PubMed:
Role of epidermal γδ T-cell-derived interleukin 13 in the skin-whitening effect of Ginsenoside F1.
PubMed:
Inhibitory effects of herbal constituents on P-glycoprotein in vitro and in vivo: herb-drug interactions mediated via P-gp.
PubMed:
Production of ginsenoside aglycons and Rb1 deglycosylation pathway profiling by HPLC and ESI-MS/MS using Sphingobacterium multivorum GIN723.
PubMed:
Metabolite profiling of ginsenoside Re in rat urine and faeces after oral administration.
PubMed:
Bioconversion of major ginsenosides Rg1 to minor ginsenoside F1 using novel recombinant ginsenoside hydrolyzing glycosidase cloned from Sanguibacter keddieii and enzyme characterization.
PubMed:
Co-transformation of Panax major ginsenosides Rbâ and Rgâ to minor ginsenosides C-K and Fâ by Cladosporium cladosporioides.
PubMed:
Microbial transformation of ginsenoside-Rgâ by Absidia coerulea and the reversal activity of the metabolites towards multi-drug resistant tumor cells.
PubMed:
Ginsenoside F1 production from ginsenoside Rg1 by a purified β-glucosidase from Fusarium moniliforme var. subglutinans.
PubMed:
Purification and characterization of a novel and unique ginsenoside Rg1-hydrolyzing β-D-glucosidase from Penicillium sclerotiorum.
PubMed:
[Pharmacokinetics of ginsenosides Rg1 and its metabolites in rats].
PubMed:
Dammarane-type glycosides and long chain sesquiterpene glycosides from Gynostemma yixingense.
PubMed:
[Metabolic study of ginsenoside Re in rats].
PubMed:
Screening of anti-platelet aggregation agents from Panax notoginseng using human platelet extraction and HPLC-DAD-ESI-MS/MS.
PubMed:
Influence of ginsenoside Rh1 and F1 on human cytochrome p450 enzymes.
PubMed:
Metabolism of ginsenoside Re by human intestinal microflora and its estrogenic effect.
PubMed:
Ginsenoside F1 protects human HaCaT keratinocytes from ultraviolet-B-induced apoptosis by maintaining constant levels of Bcl-2.
PubMed:
Degradation of ginsenosides in humans after oral administration.
PubMed:
Enzymatic preparation of ginsenosides Rg2, Rh1, and F1 from protopanaxatriol-type ginseng saponin mixture.
PubMed:
Enzymatic preparation of ginsenosides Rg2, Rh1, and F1.
PubMed:
[Saponins with low sugar chain from the leaves of Panax notoginseng (Burk) F. H. Chen].
PubMed:
Effects of ginsenosides from Panax ginseng on cell-to-cell communication function mediated by gap junctions.
PubMed:
[Studies on saponins from the leaves of Panax japonicus var. bipinnatifidus(Seem.)Wu et Feng].
PubMed:
[Isolation and identification of saponin IV, V, VI and VII in ginseng stems].